Summary: Evolutionary adaptations that allow animals like yaks and Tibetan antelopes to thrive at 14,700 feet may provide a breakthrough for human neurodegenerative diseases. A study reveals that a mutation in the Retsat gene—common in high-altitude species—protects the brain from low oxygen and promotes the regeneration of the myelin sheath.
By identifying a specific metabolite called ATDR (derived from Vitamin A), researchers successfully repaired nerve damage in mouse models of Multiple Sclerosis (MS) and cerebral paralysis, offering a natural pathway to heal the brain from within.
Key Facts
- The Retsat Mutation: Animals on the Tibetan Plateau carry a specific mutation on the Retsat gene that maintains healthy brain function despite chronic oxygen deprivation.
- Myelin Protection: In newborn mice exposed to thin-air conditions (13,000+ feet), those with the Retsat mutation showed significantly better learning, memory, and higher myelin density.
- The ATDR Breakthrough: The mutation increases enzymatic activity that converts Vitamin A into ATDR. This molecule triggers the maturation of oligodendrocytes—the “factory” cells that build and repair myelin.
- MS Treatment Potential: When mice with an MS-like disease were given ATDR, their motor function improved and their disease severity decreased.
- A Natural Alternative: Unlike current MS treatments that focus on suppressing the immune system, ATDR leverages a molecule already present in the human body to actively repair damage.
Source: Cell Press
A genetic mutation that helps animals like yaks and Tibetan antelopes survive at high altitudes may hold the key to repairing nerve damage in conditions such as cerebral paralysis and multiple sclerosis (MS).
The finding, publishing March 13 in the Cell Press journal Neuron, reveals a naturally existing pathway that promotes regeneration after nerve damage and could open new doors for treating diseases like MS by leveraging molecules that are already present in the human body.
“Evolution is a great gift from nature, providing a rich diversity of genes that help organisms adapt to different environments,” says corresponding author Liang Zhang of Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. “There is still so much to learn from naturally occurring genetic adaptations.”
The myelin sheath is a protective layer that surrounds nerve fibers in the brain and spinal cord, allowing nerve signals to transmit efficiently. Insufficient oxygen during brain development can damage this layer, leading to conditions like cerebral paralysis in newborns.
In adults, injuries to the myelin sheath are tied to MS, an autoimmune disease in which the immune system mistakenly attacks and destroys the myelin sheath. Reduced blood flow to the brain, often associated with aging, can also damage myelin, contributing to conditions such as cerebral small vessel disease and vascular dementia.
In previous studies, researchers have found that animals living on the Tibetan Plateau—which has an average elevation of 14,700 feet—carry a mutation on a gene called Retsat. Scientists suspected that this mutation helps animals like yaks and Tibetan antelopes maintain healthy brain function despite chronically low oxygen levels.
Zhang and his team set off to investigate if this mutation could prevent myelin sheath damage. They exposed newborn mice to low-oxygen conditions equivalent to elevations above 13,000 feet for about a week.
Mice carrying the Retsat mutation performed significantly better in learning, memory, and social behavior tests than those with the standard version of the gene. Brain analyses also revealed that the high-altitude gene mice had higher levels of myelin surrounding their nerve fibers.
The researchers then examined whether the Retsat mutation could repair myelin sheath damage similar to that seen in MS. They found that in mice carrying the mutation, the myelin sheath regenerated much faster and more completely after injury. The injury sites also had more mature oligodendrocytes, a type of cell responsible for producing myelin.
Further investigation showed that mice with the mutation produced higher levels of ATDR, a metabolite derived from vitamin A, in their brains. The Retsat mutation appeared to increase the enzymatic activity that converts vitamin A into its metabolites, which in turn promotes the production and maturation of myelin-producing oligodendrocytes. When the team gave ATDR to mice with an MS-like disease, their disease severity decreased, and they showed improved motor function.
Current treatments for MS mainly focus on suppressing immune activity, notes Zhang. “ATDR is something everyone already has in their body. Our findings suggest that there may be an alternative approach that uses naturally occurring molecules to treat diseases related to myelin damage,” he says.
Funding:
This work was supported by the National Science and Technology Major Project, the National Natural Science Foundation of China, the China Postdoctoral Science Foundation, Shanghai Post-doctoral Excellence Program, the Natural Science Foundation of Shanghai, the 2024 Tibet Autonomous Region Science and Technology Plan Key R&D and Transformation Project, the Open Research Fund of Navy Medical University Basic Medical College, Yunnan Revitalization Talent Support Program Science &
Key Questions Answered:
A: It’s all about surviving harsh conditions. High-altitude animals evolved to protect their brain’s “wiring” (the myelin sheath) even when oxygen is low. Humans with MS suffer from damage to that same wiring. By studying how yaks keep their myelin healthy, scientists found a “repair switch” in the Retsat gene that we can potentially flip in humans using natural molecules.
A: No, and that’s the exciting part. Most MS drugs just stop the immune system from attacking the brain. This discovery is about regeneration. It focuses on the cells that actually rebuild the protective coating around your nerves, meaning it could actually heal the damage that has already been done.
A: Not necessarily. The secret isn’t just having Vitamin A; it’s the brain’s ability to convert it into the specific metabolite ATDR. The Retsat mutation makes that conversion super-efficient. The goal for future medicine is to provide ATDR directly to the brain to kickstart the repair process without needing the genetic mutation.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this genetics and neurology research news
Author: Julia Grimmett
Source: Cell Press
Contact: Julia Grimmett – Cell Press
Image: The image is credited to Neuroscience News
Original Research: Open access.
“A Gain-of-Function Retsat Variant from High-Altitude Adaptation Promotes Myelination via a Neuronal Dihydroretinoic Acid-RXR-γ Pathway” by Daopeng Li, Wenxiu Dai, Li Li, Zhihao Zhou, Zhenghao Li, Chenzhao He, Xiangying Li, Xiaoyun Lu, Qiuying Huang, Yanqin Zhu, Debao Wu, Jiaquan Lu, Yiting Yuan, Yanghanchen Zhao, Wenbiao Zhang, Zhiping Zeng, Qiuying Huang, Xuemin Wang, Peng Shi, and Liang Zhang. Neuron
DOI:10.1016/j.neuron.2026.01.013
Abstract
A Gain-of-Function Retsat Variant from High-Altitude Adaptation Promotes Myelination via a Neuronal Dihydroretinoic Acid-RXR-γ Pathway
Evolutionary adaptations provide a powerful lens for discovering fundamental regulators. By studying a Retsat variant (Q247R) found in high-altitude-adapted species, we reveal a central pathway governing CNS myelination and repair. Mice harboring this variant show reduced neonatal hypoxia-induced hypomyelination and exhibit enhanced remyelination in adulthood.
The variant exhibits heightened enzymatic activity, driving increased neuronal production of all-trans-13,14-dihydroretinol (ATDR). By ruling out an intrinsic role in oligodendrocytes, we define this pathway as non-cell autonomous.
ATDR is converted in neurons to all-trans-dihydroretinoic acid, which acts as a neuron-to-glia paracrine signal to activate the RXR-γ pathway in oligodendrocyte progenitor cells, thereby stimulating their differentiation and myelination. Administration of ATDR, a prodrug, potently promotes remyelination in multiple myelin injury models.
Our work identifies Retsat and dihydroretinoids as pivotal regulators of white matter integrity and as a promising therapeutical avenue inspired by evolutionary genetics for white matter diseases.
